Navigation Links
FDA Approves Ranbaxys Allergy Drug

India's drug major Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market a pill to treat rhinitis, one of the most common illnesses in the US.

Affecting more than 50 million people in US, rhinitis is marked by bouts of sneezing and itching, or a runny or stuffy nose that do not seem to go away.

Total annual market sales for the approved drug Fexofenadine Hydrochloride tablets were $931 million last year.

"We are pleased to receive this tentative approval for Fexofenadine Hydrochloride Tablets. This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA," said Jim Meehan, Vice President of Sales and Marketing for Ranbaxy Pharmaceuticals Inc (RPI) Friday.

"This will further expand our product portfolio of affordable generic alternatives which have a favorable impact on the economics of the US healthcare system," he said.

Based in Jacksonville, Florida, RPI is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.


'"/>




Page: 1

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... , ... December 05, 2016 , ... ... Plastic Surgery, is excited to announce the arrival of the newest Sciton laser ... with the ability to use tunable non-ablative and ablative wavelengths for exceptional results. ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... 05, 2016 , ... Worldwise ®, a leading consumer ... kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise CEO. ... agreement three years ago to design and develop the kathy ireland® Loved Ones™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
(Date:12/5/2016)... , ... December 05, 2016 , ... BSI and Brenntag ... United States and Canada for distribution of their natural fruits and beverage ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016   Mallinckrodt Pharmaceuticals (NYSE: ... company, today announced that it received a perfect score ... (CEI), a national benchmarking survey and report on corporate ... transgender (LGBT) workplace equality, administered by the Human Rights ... major U.S. businesses which also earned top marks this ...
(Date:12/5/2016)... , Dec. 5, 2016 Special purpose needles are ... such as fluid and cells from organs or lumps and ... and sizes. The global market for special purpose needles is ... In terms of revenue, the global special purpose needles market ... the forecast period (2016–2026) and is expected to be valued ...
(Date:12/5/2016)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 2 clinical study of sotagliflozin, a dual SGLT1 and ... the leading global organization funding type 1 diabetes research. ... trial, which randomized a total of 87 patients, was ... dose of sotagliflozin compared to a placebo control in ...
Breaking Medicine Technology: